Masthead for article titled, "Bamlanivimab therapy for acute COVID-19 does not blunt SARS-CoV-2-specific memory T cell responses"

ACTIV-2/A5401 Study Results

15 November 2022

In this study, findings suggest that the quantity and quality of SARS-CoV-2-specific T cell memory was robust in individuals who received bamlanivimab for acute COVID-19. Receipt of bamlanivimab during acute COVID-19 neither diminished nor enhanced SARS-CoV-2-specific cellular immunity.

Journal Masthead with title of the study: Predictors of SARS-CoV-2 RNA from nasopharyngeal swabs and concordance with other compartments in non-hospitalized adults with mild to moderate COVID-19

ACTIV-2/A5401 Study Results

11 November 2022

In this study, SARS-CoV-2 RNA shedding was concordant across compartments. Age was strongly associated with viral shedding and men had slower viral clearance than women, which could explain sex differences in acute COVID-19 outcomes.

Masthead for a journal article titled, "Emergence of SARS-CoV-2 escape mutations during Bamlanivimab therapy in a phase II randomized clinical trial"

ACTIV-2/A5401 Study Results

26 October 2022

The results from this study highlight the potential for rapid emergence of resistance during mAb monotherapy treatment that results in prolonged high-level respiratory tract viral loads. Assessment of viral resistance should be prioritized during the development and clinical implementation of antiviral treatments for COVID-19.

Masthead for journal article titled, "HIV RNA screening reduces integrase strand transfer inhibitor resistance risk in persons receiving long-acting cabotegravir for HIV prevention"

HPTN 083 Study Results

14 October 2022

When using CAB-LA PrEP, earlier detection of HIV infection with a sensitive RNA assay may allow for earlier treatment initiation with the potential to reduce INSTI resistance risk. Further studies are needed to evaluate the value and feasibility of HIV RNA testing with CAB-LA PrEP.

Masthead for article titled, "Nasal and Plasma SARS-CoV-2 RNA Levels are Associated with Timing of Symptom Resolution in the ACTIV-2 Trial of Non-hospitalized Adults with COVID-19"

ACTIV-2/A5401 Study Results

10 October 2022

Acute COVID-19 symptoms limit daily activities, but little is known about its association with SARS-CoV-2 viral burden. In this exploratory analysis of placebo recipients in the ACTIV-2/A5401 platform trial, we showed that high anterior nasal (AN) RNA levels and detectable plasma RNA were associated with delayed symptom improvement.

Masthead for articled titled, "Sex Differences in Subclinical Atherosclerosis and Systemic Immune Activation/Inflammation Among People With Human Immunodeficiency Virus (HIV) in the United States"

REPRIEVE Study Results

14 September 2022

Among people with HIV, sex differences in presentations of atherosclerotic cardiovascular disease may be influenced by differences in coronary plaque parameters, immune/inflammatory biomarkers, or relationships therein. In this study, among US people with HIV, females had a lower prevalence of plaque and noncalcified portion or vulnerable features, as well as differences in key immune/inflammatory biomarkers. Immune-plaque relationships differed by sex for D-dimer but not other tested parameters.

Masthead for article titled, "Evaluating group-sequential non-inferiority clinical trials following interim stopping: The HIV Prevention Trials Network 083 trial"

HPTN 083 Study Results

02 September 2022

For the HIV Prevention Trials Network 083 trial, the difference between corrected inferential statistics and naive results was quite small-as will often be the case-nevertheless, it is appropriate to report and publish the most accurate and unbiased statistical results.

Masthead for an article titled, "Liver inflammation is common and linked to metabolic derangements in persons with treated HIV"

A5322 Study Results

01 September 2022

In this study, alanine aminotransferase elevation was common in this cohort of people with HIV and associated with metabolic disease and hepatic steatosis markers. Nonalcoholic fatty liver disease is likely a common cause of liver inflammation in people with HIV receiving suppressive antiretrovirals, deserving targeted diagnosis and intervention.

Masthead for article titled, "Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19"

ACTIV-2/A5401 Study Results

22 August 2022

This study provides evidence of faster reductions in nasopharyngeal SARS-CoV-2 RNA levels but not shorter symptom durations in non-hospitalized adults with early variants of SARS-CoV-2.

Masthead for article titled, "Cytomegalovirus Immunoglobulin G (IgG) Titer and Coronary Artery Disease in People With Human Immunodeficiency Virus (HIV)"

REPRIEVE Study Results

17 August 2022

In this study, no meaningful association was seen between Cytomegalovirus immunoglobulin G (CMV IgG) titer and coronary artery disease indexes among antiretroviral therapy-treated people living with HIV at study enrollment. Longitudinal assessments in REPRIEVE will determine the relationship of CMV IgG titer to plaque progression and cardiovascular events.